A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.

Abstract

Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.

• Authors: T R Jenkins, C Tangen, J S Macdonald, G Weiss, R Chapman, A Hantel
• Journal: Investigational new drugs (Invest New Drugs) Vol. 11 Issue 4 Pg. 329-31 (Nov 1993) ISSN: 0167-6997 [Print] United States
• PMID: 8157474 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anthraquinones
• Antineoplastic Agents
• Pyrazoles
• piroxantrone

Topics

• Adenocarcinoma (drug therapy, secondary)
• Adult
• Aged
• Anthraquinones (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Pancreatic Neoplasms (drug therapy)
• Pyrazoles (adverse effects, therapeutic use)